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Abstract
Treatment options for pancreatic cancer have shown limited success mainly owing to poor selectivity for pancreatic
tumor tissue and to a lack of activity in the tumor. In this study, we describe the ability of the urokinase-type plasmin-
ogen activator receptor (uPAR) promoter to efficiently and selectively target pancreatic tumors andmetastases, which
enables the successful management of pancreatic cancer. We have generated a replication-defective reporter adeno-
virus, AduPARLuc, and a conditionally replicating adenovirus, AduPARE1A, and we have studied the selectivity and
antitumoral efficacy in pancreatic tumors and metastases. Toxicity was studied on intravascular delivery. We demon-
strate that the uPAR promoter is highly active in pancreatic tumors but very weak in normal tissues. Tumor specificity
is evidenced by a 100-fold increase in the tumor-to-liver ratio and by selective targeting of liver metastases (P< .001).
Importantly, the AduPARE1A maintains the oncolytic activity of the wild-type virus, with reduced toxicity, and exhibits
significant antitumoral activity (25% tumor eradication) and prolonged survival in pancreatic xenograft models (P <
.0001). Furthermore, upon intravascular delivery, we demonstrate complete eradication of liver metastasis in 33%
of mice, improving median survival (P = 5.43 × 10−5). The antitumoral selective activity of AduPARE1A shows the
potential of uPAR promoter–based therapies in pancreatic cancer treatment.
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Introduction
Pancreatic cancer is one of the most aggressive and devastating human
malignancies in developed countries. Overall survival rate is less than
4%, with almost all patients dying within the first year after diag-
nosis as a result of the rapid spreading of the tumor or metastatic
dissemination [1].
Up to now, pancreatic cancer treatment has mainly been palliative be-
cause of the ineffectiveness of current treatments [1]. Despite the great
efforts made to improve therapy, even the very latest therapeutic ap-
proaches assayed, such as the combination of gemcitabinewith epidermal
growth factor receptor–targeting agents, have shown only partial im-
provement on patients survival [2]. Thus, there is an urgent need for
more intensive research seeking ways to treat this devastating disease.
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The most important challenge to the development of a safe and ef-
fective treatment of pancreatic cancer is the identification of a selective
therapeutic agent capable of potent activity both in primary tumors and
in tumor metastases with low toxicity when administered systemically.
Recently, oncolytic adenovirus therapy, based on restricting viral repli-
cation to cancer cells, has emerged as a promising candidate for cancer
therapy [3]. The phase 1/2 clinical trials assaying the oncolytic efficacy
of ONYX-015 have shown no major toxicity on intravascular infusion
[4] but only partial therapeutic benefit when administered intratumor-
ally to pancreatic tumors [5]. Therefore, the remaining issue is still to
obtain a virus with sufficient activity and selectivity to the tumor tissue.
To achieve tumor-selectivity, several tumor-specific promoters (TSPs)
have been assayed for pancreatic cancer. However, they have shown
lower activity in comparison to ubiquitously active promoters such as
the cytomegalovirus (CMV) [6,7], unless the cholecystokinin type A
receptor promoter when engineered with a VP16-GAL4-WPRE inte-
grated systemic amplifier [8]. When used in the context of condition-
ally replicative adenovirus, although significant responses have been
reported for candidate TSP when administered intratumorally, limited
antitumor activity has been observed on established xenografts upon
intrasvascular delivery, and no studies have been performed on meta-
static models [9–11].
The urokinase-type plasminogen activator receptor (uPAR) is a
glycosylphosphatydilinositol-anchored protein that binds with high
affinity uPA, pro-uPA, amino terminal fragments of urokinase, and
other cell receptors. The uPAR has an active role in cancer because it
regulates cell migration, adhesion, metastasis, and tumor growth [12].
In pancreatic cancer and in tumor metastasis, uPAR has been found to
be overexpressed [13,14].
Several reports have shown that the down-regulation of uPAR expres-
sion with uPAR antagonists, small interfering RNA, or antisense genes
prevents tumor growth, invasion, and metastasis [15]. Bauer et al. [16]
also described how combining gemcitabine and a monoclonal antibody
against uPAR reduces pancreatic cancer invasion in orthotopic tumors.
In the present study, we have also targeted uPAR expression in
pancreatic cancer but using a completely different approach. We have
validated the uPAR promoter to selectively target adenovirus gene ex-
pression and replication to primary pancreatic tumors and metastases.
To our knowledge, for the first time, the present study demonstrates
that upon intravascular injection, uPAR promoter activity is very weak
in normal tissues, whereas in pancreatic tumor models and liver metas-
tases, uPAR promoter activity is similar to that of the CMV promoter.
Importantly, our results show that the conditionally replicative adeno-
virus AduPARE1A, in which replication is controlled by the human
uPAR promoter, eradicates pancreatic tumors and tumor metastasis.
Materials and Methods
Plasmid Constructs
A 450-bp fragment encompassing the −402/+48 region of the uPAR
promoter was excised from pCAT-Basic-uPAR(C2) [17] and subcloned
into a pAdTrack to generate pAdTrackuPARp. The cDNA from lucif-
erase was excised from the pGL3-Enhancer (Promega, Madison, WI)
plasmid and subcloned into the pAdTrackuPARp to generate pAd-
TrackuPARLuc.
Cell Lines
The human pancreatic adenocarcinoma cell lines PANC-1, BxPC-3,
RWP1, NP-31, NP-9, and NP-18 were obtained and cultured as pre-
viously described [18]. A549 human lung cancer cells, MCF-7 human
breast cancer cells, NIH3T3 murine fibroblasts, IMR-90 human
lung fibroblasts, and HEK293 were obtained from the American
Type Culture Collection (ATCC, Rockville, MD) and maintained as
already described [18,19]. U2 OS human osteosarcoma cells were ob-
tained from European Collection of Cell Cultures (Wiltshire, United
Kingdom) and were cultured following the manufacturer’s descrip-
tion. Human pancreatic ductal epithelial (HPDE) cells were kindly
provided by Dr. F.X. Real (IMIM, Barcelona, Spain) and cultured and
maintained as reported [20]. Luciferase-expressing cells PANC-1-Luc
were established by transducing the parental cells with luciferase recom-
binant retrovirus. Briefly, pLHCLuc retroviral vector was transfected
by the calcium/phosphate–DNAprecipitation method into the ampho-
tropic packaging cell line Phoenix Ampho (ATCC, Rockville,MD), and
48 hours after transfection, viral supernatant was collected, passed
through 0.45-nm filters, and used for transduction. Twenty-four hours
later, cells were selected in 0.2 mg/ml hygromycin. Cells were cloned
and tested for luciferase expression.
Transfection
Transient transfections were performed in NIH3T3, HPDE, and
RWP1 cells, 24 hours after seeding, with SuperFect Transfection Re-
agent (Qiagen, Hilden, Germany) according to the manufacturer’s pro-
tocol using 3 μg of plasmid DNA. Three micrograms of pCMV
β-galactosidase plasmid was cotransfected to normalize for transfection
efficiency.
Adenoviruses
Replication-defective adenoviruses AdCMVGFPLuc and AduPAR-
Luc express the firefly luciferase gene under the control of CMV or
uPAR promoter, respectively. AdCMVGFPLuc has already been
described [21]. The AduPARLuc was generated by the homologous
recombination of the pAdTrackuPARLuc and the adenoviral genome
following a standard protocol.
The oncolytic AduPARE1A was constructed by inserting the uPAR
promoter (450-bp fragment) upstream of an E1a adenoviral gene in
which the E1a translation start site was replaced by the Kozak sequence.
The human DM-1 insulator was cloned upstream the uPAR pro-
moter [9,22]. All cassettes were cloned in a left-to-right orientation.
The wild-type virus, Adwt, was obtained from the ATCC (Manassas,
VA). Replication-defective AdV has already been described [23].
Replication-defective viruses and Adwt were propagated in HEK293
cells, and the oncolytic AduPARE1A virus was amplified in RWP1
cells. All viruses were purified by standard cesium chloride banding.
The physical particle concentration (vp/ml) was determined by optical
density reading (OD250), and the plaque-forming units (pfu/ml) were
determined by tissue culture infectious dose50 titration on HEK293
cells. AdCMVGFPLuc and AduPARLuc presented an equal ratio of
vp and pfu.
Tumor Growth Studies
BxPC-3 cells (2.5 × 106) were injected subcutaneously (SC) into
each posterior flank of BALB/c nude mice (Charles River France,
Lyon, France). Tumors were measured three times a week, and volumes
were calculated according to the formula V (mm3) = larger diameter
(mm) × smaller diameter 2 (mm2) / 2. Treatment was initiated when
tumors achieved a mean volume of 50 mm3. All animal procedures
met the guidelines of European Community Directive 86/609/EEC
and were approved by the local ethical committee.
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Bioluminescence Assay and Quantification
Animals were anesthetized and the substrate D-Firefly-Luciferin
(Xenogen, Alameda, CA) was administered intraperitoneally (32 mg/kg).
Luciferase activity was visualized and quantified using an in vivo
bioluminescent system (IVIS50; Xenogen) and Living Image 2.20.1
Software overlay on Igor Pro4.06A software (Wavematrics, Seattle,
WA) as described [23]. Luciferase activity was quantified from non-
saturated images, measuring the total amount of emitted light recorded
by the CCD camera.
Immunohistochemistry and Stereological Analysis
Five-micrometer sections were deparaffinized, rehydrated, and treated
with 10 mM citrate buffer (pH 6.0) for antigen retrieval. Sections were
then incubated overnight with a rabbit anti–luciferase polyclonal anti-
body (1:500; Sigma, Poole, United Kingdom). Bound antibodies were
detected with Universal LSAB+ (DAKO Diagnostics, Denmark). Sec-
tions were counterstained with Mayer’s hematoxylin. All sections were
examined on a Leica DMR microscope (Leica, Madrid, Spain).
A physical dissector method was used to estimate the luciferase-
positive cells per squared millimeter in both the liver and tumoral
areas, with the aid of a CAST-GRID software package (Olympus,
Denmark) adapted to an Olympus BX51 microscope. At least three
independent, nonsequential, randomly selected liver sections or three
tumor sections were counted from each animal. A mean of 25 dissector
probes (dis), of 17,110 μm2 (Sdis), were analyzed per liver area with a
×10 lens. A mean of 160 dissector probes of 57,043 μm2 was analyzed
per tumoral area with a ×40 lens. The total final surface area analyzed
was similar for each of the different viral groups. The number of
cells per squared millimeter was calculated according to the formula:
[N (cells/mm2) = N cells/N dis × Sdis].
Liver Toxicity Studies and Determination of the Adenoviral
DNA Content in Liver
For liver toxicity studies, 6- to 8-week-old immunocompetent
BALB/c male mice received a single administration of the corres-
ponding virus at a final dose of 2 × 1010 vp (AduPARLuc) or 5 ×
1010 vp (AduPARE1A) in a final volume of 0.2 ml injected into the
tail vein. Body weight, morbidity, and moribundity were monitored
daily. Blood samples were collected by intracardiac puncture under
anesthesia. Serum aspartate aminotransferase (AST) and total biliru-
bin (BLT) were determined on an Olympus AU400 Analyzer. Subse-
quently, the animals were killed, and liver portions were either frozen
for luciferase or viral DNA determination or fixed and embedded in
paraffin for hematoxylin and eosin staining or frozen in OCT (Akura
Finetek, Zoeterwoude, the Netherlands) for E1A immunodetection.
E1a immunodetection was performed by incubating the OCT-
embedded liver sections with a primary polyclonal antibody anti–
adenovirus-2 E1a (clone 13 S-5; Santa Cruz Biotechnology, Heidelberg,
Germany). AlexaFluor 488–labeled goat anti–rabbit antibody (Molecu-
lar Probes, Eugene, OR) was used as a secondary antibody. The nuclei
were counterstained with 5 μg/ml bis-benzimide (Hoechst 33342;
Sigma) and visualized under a fluorescent microscope (Observer/Z1;
Zeiss, Barcelona, Spain). The fluorescent images were captured using
a digital camera (AxioCamMRm; Zeiss).
When stated, DNAwas obtained from frozen liver tissue by incubat-
ing in a buffer containing 0.2 mg/ml RNaseA and 0.1 mg/ml protease
overnight at 55°C. The liver adenoviral DNA content was determined
with real-time polymerase chain reaction (PCR; 100 ng of DNA) and
SYBERGreen IMaster Plus mix (RocheDiagnostics, Barcelona, Spain).
Hexon primer sequences were as follows: forward 5′ GCCGCAGT-
GGTCTTACATGCACATC 3′ and reverse 5′ CAGCACGCCGC-
GGATGTCAAAG 3′. The adenovirus copy number was quantified
with a standard curve, consisting of adenovirus DNA dilutions (10-
107 copies) in a background of liver mouse genomic DNA. Samples
and standards were amplified in triplicate, and the average number of
total copies was normalized to copies per cell based on the input DNA
weight amount and a genome size of 6 × 109 bp/cell. Results are ex-
pressed as vp/100 cells.
Statistical Analysis
The descriptive statistical analysis was performed on SPSS software
(SYSTAT software, Inc, Chicago, IL). Results are expressed as mean ±
SEM. A Mann-Whitney nonparametric test was used for the statistical
analysis (2-tailed) of in vitro and in vivo studies. P < .05 was taken as
the level of significance.
The in vivo tumor growth and survival statistical analysis was
performed using S-PLUS functions. In line with the experimental
design, animal, repeated measures, and site are considered to be nested
classification factors. We associated random-effects terms with the ani-
mal factor, the day of measurement, and the site of nesting of the ani-
mal. Hence, general linear-mixed models were used to estimate the
effects of treatment on tumor growth by taking nested and repeated
design into account [24]. These models allowed us to analyze the over-
all effect and the effect of each treatment. The estimation of the coeffi-
cients and associated P values was based on restricted maximum
likelihood. A plot with residual versus fitted values was used to check
the assumptions of the model. With these plots, log transforma-
tion of the data was used when homoscedasticity was observed. The
variance function structure was used to model heteroscedasticity in
the day-to-day errors. P < .05 (Bonferroni correction) was considered
statistically significant after performing multiple comparisons of the
treatment groups.
Survival analyses were also performed to analyze time-to-event prob-
ability. The survival curves obtained were compared for the different
treatments. Animals whose tumor size never achieved the threshold
or that were alive at the end of the experiment were included as right
censored information. A log-rank test was used to determine the statis-
tical significance of the differences in time-to-event. P .05 was consid-
ered statistically significant.
Results
uPAR Promoter Drives Adenoviral Transgene Expression
to Pancreatic Cancer In Vitro and In Vivo
We analyzed uPAR expression in a panel of pancreatic cancer cell
lines, in pancreatic tumors, and in HPDE cells derived from normal
ductal epithelium by semiquantitative reverse transcription (RT)–
PCR analysis. uPAR expression was weaker in normal ductal HPDE
cells when compared with most of the cancer cells (FigureW1A). uPAR
expression was also detected in the two different tumor models analyzed
(Figure W1B). To initially test the pancreatic cancer selectivity of the
uPAR promoter, reporter studies were undertaken. Results showed that
a 450-bp fragment of uPAR promoter was significantly more active in
RWP1 pancreatic cancer cells than in nontumoral cells HPDE or
NIH3T3 (Figure 1A).
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To assess the potential capacity of the uPAR promoter to effectively
and selectively target pancreatic cancer, we generated a replication-
defective adenovirus, AduPARLuc, which expresses the luciferase re-
porter gene under the regulation of a 450-bp fragment of the human
uPARpromoter (Figure 1B). TheAdCMVGFPLuc virus, which expresses
the luciferase gene under the CMV promoter, was used as a control.
All pancreatic cancer cells infected with the AduPARLuc virus
showed high levels of luciferase activity, indicating that the uPAR pro-
moter was active in pancreatic cancer cells. However, when compared
with CMV promoter, uPAR promoter activity resulted in 23% to 27%
of that of the CMV (Figure 1B). Interestingly, the 450-bp fragment of
the uPAR promoter had relatively higher luciferase activity in pancreatic
Figure 1. uPAR promoter activity in pancreatic cancer cell lines and in pancreatic tumors. (A) NIH3T3, HPDE, and RWP1 cells were
transfected with the plasmid pAdTrackuPARLuc (shown in the scheme). To normalize for transfection efficiency, pCMVβGal plasmid
was used. Forty-eight hours later, luciferase and β-galactosidase activities were determined. Results are expressed as light units (LU)
relative to β-galactosidase activity and are shown as the mean ± SEM of three independent experiments. **P = .006, HPDE versus
RWP1; **P = .002, NIH3T3 versus RWP1. (B) A total of 20,000 cells/well were seeded in triplicate and infected with either AduPARLuc
or AdCMVGFPLuc at 104 vp/cell. Luciferase activity was quantified 72 hours after viral transduction and normalized to total protein
levels. Results are expressed as light units per microgram protein. Values are represented as the mean ± SEM of four independent
experiments. (C) Percentage of uPAR/CMV luciferase ratio relative to the uPAR/CMV luciferase ratio for RWP1 cells. Values are repre-
sented as the mean ± SEM of three or four independent experiments. *P< .05. (D) A total of 3 × 106 BxPC-3 cells were injected SC into
each posterior flank of nude mice. When tumors achieved a mean volume of 100 mm3, they were randomized and injected intratumor-
ally with a single 2.5 × 1010 vp dose of AdCMVGFPLuc (n = 9) or AduPARLuc (n = 10). Shown are representative images and quanti-
fication of bioluminescent emission from mice receiving AdCMVGFPLuc (upper panel) or AduPARLuc (lower panel) at days 3, 6, and 10
after viral injection. Results are expressed as photons per second. Values are represented as mean ± SEM. *P = .03.
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cancer cells and in cells of other cancer origin (lung, breast, and bone)
than in the nontumor cells lines HPDE and IMR-90 (Figure 1C). This
then indicates that the uPAR promoter retains its specificity for cancer
cells in the context of an E1A-deleted adenoviral genome.
To identify uPAR activity in pancreatic tumors, BxPC-3 SC xeno-
grafts were injected with AduPARLuc or AdCMVGFPLuc at 2.5 ×
1010 vp/tumor, and the level and duration of luciferase expression were
monitored by optical imaging. Bioluminescence imaging showed that
both viruses induced high levels of luciferase expression (Figure 1D).
In mice receiving the control AdCMVGFPLuc virus, luciferase activity
peaked at day 3 but rapidly decreased, showing a significant four-fold
reduction in the initial luciferase activity at day 6 after viral injection
(Figure 1D). By contrast, in AduPARLuc-injected tumors, biolumines-
cence activity was maintained constant, lasting at least 10 days after viral
injection. It is worthy of note that from day 6 to the end of the exper-
iment, both promoters presented similar levels of activity. Similar results
were obtained with anNP-18 SC tumormodel (data not shown). These
findings indicated that uPAR promoter activity in pancreatic tumors is
as high as that of the constitutively active CMV promoter (Figure 1D).
uPAR Promoter Selectively Targets Pancreatic Cancer Tumors
To address the potential selectivity of the AduPARLuc virus for pan-
creatic cancer tumors, mice bearing BxPC-3 and PANC-1 xenografts
were challenged with a single intravenous (IV) injection of 5 × 1010 vp
of the AduPARLuc virus. Luciferase expression was then analyzed in
the liver and in the tumors. Data showed that the uPAR promoter activ-
ity was as high as that of the CMV in the tumor, whereas a signifi-
cant reduction in transgene expression was detected in the liver of
AduPARLuc-injected animals (Figure 2, A and B). The cancer-specific
index (established as a tumor-to-liver ratio) was significantly higher in
AduPARLuc-injected animals in both BxPC-3 (122-fold, P = .001)
and PANC-1 (23-fold, P = .006) SC tumor models (Figure 2, C and
D), indicating that the uPAR promoter was more selective for pancreatic
tumor tissue in vivo. These results are consistent with the results obtained
from the biodistribution studies, where a significantly lower uPAR activ-
ity was detected in the liver, spleen, kidneys, heart, and lung, and a very
weak activity was observed in the pancreas, intestine, stomach, and testis
(Figure W2).
AduPARE1A Induces Significant Cytotoxicity in Pancreatic
Cancer Cells
To study whether the uPAR promoter could be a candidate promoter
to selectively, efficiently, and safely act against pancreatic cancer, we
generated an oncolytic AduPARE1A virus in which the E1A gene ex-
pression was regulated by the uPAR promoter. A Kozak sequence was
engineered upstream of the E1A gene to increase its replication potency
[9]. A DNA fragment from the myotonic dystrophy locus (DM-1),
with enhancer-blocking insulator activity, was introduced upstream
the uPAR promoter to isolate it from enhancer and transcriptional units
from the adenovirus genome [22] (Figure 3A).
We tested the cytotoxic effect of AduPARE1A in four pancreatic can-
cer cell lines and in HPDE cells infected with different doses of Adu-
PARE1A or Adwt. The results showed that the AduPARE1A dose
required to cause a 50% reduction in cell viability (ID50) was equivalent
Figure 2. uPAR promoter tumor-to-liver ratio. A total of 3 × 106 BxPC-3 cells (A and C) or 2.5 × 106 PANC-1 cells (B and D) were injected
SC into each posterior flank of nude mice. Once tumors were established, animals received 5 × 1010 vp of AdCMVGFPLuc (n = 4 mice;
n = 8 tumors) or AduPARLuc (n = 4 mice; n = 8 tumors) or saline solution (n = 2 mice; n = 4 tumors) through the tail vein. Mice were
killed 5 days after virus injection, and tumor and liver extracts were assayed for luciferase activity. (A and B) Luciferase activity from liver
and tumor tissues. Luciferase activity from the saline group was considered background and subtracted from the viral groups. Results
are expressed as light units per milligram of tissue (LU/mg). Values are represented as mean ± SEM. **P < .01, ***P < .001. (C and D)
Tumor-to-liver ratio. Values are represented as mean ± SEM of tumor RLU relative to liver RLU. **P < .01.
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Figure 3. Antitumoral effect of AduPARE1A in pancreatic cancer cells lines, HPDE cells and in BxPC-3 SC xenografts. (A) Schematic
representation of the AduPARE1A and Adwt viruses. DM indicates myotonic dystrophy fragment; K , Kozak sequence. (B) A total of 3 ×
103 cells/well were seeded in triplicate and infected with a dose range of 0 to 10 multiplicities of infection of Adwt or AduPARE1A. Cell
viability was measured by MTT assay 4 days later and is expressed as the percentage of absorbance of treated wells compared with that
of mock-infected cultures. Dose-response curves and ID50 values, obtained by a standard nonlinear model based on the Hill equation,
are shown as the mean ± SEM of three independent experiments. –•–, Adwt; –▵–, AduPARE1A. (C) Animals bearing BxPC-3 SC tumorswere randomized to four groups: two control groups, namely, saline (n = 11 tumors) and AdV (n = 11 tumors), and two treated groups,
namely, Adwt (n = 12 tumors) and AduPARE1A (n= 12 tumors). Animals received intratumoral injections of 107 pfu/tumor at days 6 and
14 after tumor implantation. Tumor growth curves are plotted as mean tumor volume ± SEM. ***P < .0001. (D) Kaplan-Meier survival
curves (log-rank test, <.0001). End point (animals with a tumor volume, ≥300 mm3).
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to the ID50 of the Adwt in the cancer cell lines but was higher for the
nontumoral cell line HPDE. These data show that AduPARE1A
displays an important cytotoxic effect in pancreatic tumor cells, with
a potency similar to that of Adwt (Figure 3B). No reduction in cell
viability was observed when a nonreplicative empty vector (AdV) was
used at similar viral doses (data not shown), demonstrating that the
cytotoxic effect observed was specifically due to viral replication and
not to nonspecific viral toxicity.
AduPARE1A Represses Tumor Growth and Prolongs Mouse
Survival in BxPC-3 SC Xenografts
Next, we evaluated the antitumoral effect of the AduPARE1A onco-
lytic virus in pancreatic tumors. BxPC-3 SC xenografts received two
injections, weekly separated, of 107 pfu/tumor of AduPARE1A or Adwt
or AdV or saline solution. As shown in Figure 3C , a significant reduc-
tion in tumoral growth was observed in both treated groups (AduPAR-
E1A and Adwt) compared with the saline or AdV control groups (P <
.0001). Importantly, 25% (3/12) of AduPARE1A-injected tumors and
16% (2/12) of Adwt-injected tumors were completely eradicated and
no tumor burden detected when some of the animals were killed owing
to the growth of the contralateral tumor. The median survival time
for mice receiving AdV control was 32 days. In contrast, the median
survival time for mice receiving AduPARE1A was 51 days (P < .01;
Figure 3D). Moreover, it is worth mentioning that one of the six mice
treated with AduPARE1A did not show any tumor burden in either of
the two injected tumors 6 months after treatment, indicating that there
was no recurrence of the tumors eradicated.
AduPARE1A Represses Tumor Growth and Prolongs Mouse
Survival in a Metastasis Tumor Model
The uPAR is a key factor in invasion and metastasis. In this respect,
high levels of uPAR expression have been described in human pancre-
atic cancer metastases [14]; therefore, we hypothesized that the uPAR
promoter could also selectively target pancreatic tumor metastasis. To
ascertain this, we first established a metastasis model by inoculating
PANC-1 cells into the spleen of nude mice (Figure W3). By day 10
of tumor cell inoculation, when metastatic liver nodules were present,
mice were injected IV with 5 × 1010 vp of AduPARLuc or Ad-
CMVGFPLuc. Luciferase immunostaining in liver sections revealed
strong immunoreactivity in PANC-1 tumor cells in both AduPARLuc-
and AdCMVGFPLuc-treated mice (Figure 4A). The proportion of
luciferase-positive tumor cells in AduPARLuc-treated mice was signifi-
cantly higher than that in AdCMVGFPLuc mice (Figure 4B). Interest-
ingly, in the liver parenchyma, luciferase expression was detected at very
low levels and in a limited number of cells in the AduPARLuc-treated
mice, whereas strong luciferase staining and a significant increased
Figure 4. AduPARLuc expression in liver metastasis model. Animals bearing PANC-1 tumor metastases received saline solution (n = 3)
or 5 × 1010 vp of AdCMVGFPLuc (n = 3) or AduPARLuc (n = 3) IV. Three days later, animals were killed, livers were excised, and
luciferase expression was determined by immunohistochemistry with a polyclonal anti–luciferase antibody. (A) Representative images
of luciferase expression in liver (a, b, c) and tumor areas (d, e, f) of animals injected with AdCMVGFPLuc or AduPARLuc or saline. (a, b, c)
Scale bar, 200 μm; original magnifications, 100 μm. (d, e, f) Scale bar, 50 μm; original magnifications, 20 μm. (B) Stereological analysis.
Quantification of luciferase-positive cells in the liver and tumor. Values are shown as the mean ± SEM of three animals. Results are
expressed as cells per total area analyzed (cells/mm2).
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proportion of luciferase-positive hepatocytes were detected in the
AdCMVGFPLuc group (Figure 4A), providing new evidence of the
selectivity of the uPAR promoter.
To evaluate the effectiveness of AduPARE1Aon themetastaticmodel,
PANC-1 luciferase-expressing cells were inoculated into the spleen of
nude mice. Six days later, once the metastases were formed (Figure 5A),
the animals were treated IVwith saline or with a single dose of 1010 vp or
5 × 1010 vp of AduPARE1A. Seven days after virus administration, both
treated groups presented lower luciferase activity than control animals
did. A significant 50% reduction in initial luciferase activity was detected
in animals receiving the highest viral dose (P = .005; Figure 5B). To
better address whether this reduction in luciferase-positive cells corre-
lated with a reduction in liver tumors, representative animals from each
group were killed at day 21 after treatment. No tumor nodules were
found in the liver parenchyma of the 5 × 1010 vp AduPARE1A-treated
mice (Figure 5C). The number of nodules found was also lower in the
animals treated with 1010 vp AduPARE1A than in saline-treated mice
(data not shown). The median survival time of the saline injected mice
Figure 5. Antitumoral effect of AduPARE1A in PANC-1-Luc liver metastasis model. PANC-1-Luc cells were injected intrasplenically into
BALB/c male mice. Six days after tumor implantation bioluminescent activity was recorded (day 0). The day after, animals received a
single IV injection, of either saline (n = 10) or AduPARE1A at 1010 vp/animal (n = 8) or AduPARE1A at 5 × 1010 vp/animal (n= 10) in a Vf =
0.2 ml. (A) Bioluminescent images of liver metastases-bearing mice at days 0 and 7 after adenoviral treatment. (B) Bioluminescent emission
quantification at day 7 relative to day 0. **P = .005, *P = .02. (C) Representative images of livers excised at day 21 after treatment. Tumor
nodules and bile duct obstruction are shown in the saline group (arrows, left panels). Normal bile duct in the 5 × 1010 AduPARE1A–injected
animals (arrow, right panels). Scale bar, 1.7 cm. (D) Kaplan-Meier survival curves. AduPARE1A 1010 vp versus saline log-rank test= .003; Adu-
PARE1A 5 × 1010 vp versus saline log-rank test = 5.43 × 10−5. End point (decreased body weight≥20% or animal experiencing jaundice).
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was 35 days, whereas the median survival time of both treated groups
was significantly longer, that is, 60 days for the 1010 vp viral dose and
70 days for the 5 × 1010 vp dose (Figure 5D). Survivingmice (33%)were
alive for more than 5 months with no symptoms of morbidity. Then,
they were killed and no tumors were observed in any abdominal organ
indicating tumor eradication.
uPAR Promoter Presents Low Liver Toxicity on IV Injection
After intravascular injection, adenoviruses liver tropism leads to liver
toxicity, caused by an immune response to the viral proteins as well as
transgene expression.
First, we evaluated the potential toxicity of AduPARLuc after IV
injection in immunocompetent mice and compared it to that of
AdCMVGFPLuc. Minimal liver histopathologic changes were observed
in AduPARLuc animals in contrast to the hepatocytotoxicity found in
all AdCMVGFPLuc liver sections. Importantly, all animals that received
the AduPARLuc virus presented AST levels within the reference range
(Figure W4). To discard differences in liver viral transduction between
the AduPARLuc- and AdCMVGFPLuc-injected mice, we assessed the
amount of viral particles in the liver by quantitative real-time PCR.
Quantification showed a similar amount of viral particles in both groups
(AdCMVGFPLuc 13.14 ± 1.33 vp/100 cells and AduPARLuc 10.82 ±
0.92 vp/100 cells) indicating that the toxicity elicited by transgene ex-
pression in the liver, in the context of a replication-defective adenovirus,
can be minimized by the uPAR promoter.
Next, we studied the potential liver toxicity of the oncolytic Adu-
PARE1A and compared it to that of Adwt. E1A Immunostaining
revealed negligible E1A expression in the liver sections of AduPAR-
E1A-injected animals, whereas strong immunoreactivity was detected
in the liver of Adwt mice (Figure 6A). Consistently, lower areas of
Figure 6. AduPARE1A toxicity studies. BALB/c immunocompetent mice received IV saline solution (n = 6) or 5 × 1010 vp of Adwt (n = 6)
or 5 × 1010 vp of AduPARE1A (n = 6). Five days later, blood samples were collected. Next, animals were killed, and the liver tissue
excised was frozen in OCT or fixed and embedded in paraffin. (A) E1A expression in the liver tissue. Nuclei were stained with Hoechst. Scale
bar, 100 μm. (B) Hematoxylin and eosin staining of liver tissue. Necrotic and swollen hepatocytes (arrows). Scale bar, 1.3 cm. (C) AST and
BLT determination. *P < .05.
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hepatocyte swelling and necrotic hepatocytes were observed in the
liver sections of AduPARE1A-injected mice compared with Adwt-
injected mice (Figure 6B). Moreover, serum levels of AST and BLT
were significantly lower in AduPARE1A-injected mice than those in
Adwt-injected mice (Figure 6C ). Furthermore, a 50% mortality rate
was detected in the 5 × 1010 vp Adwt-injected animals, whereas all
the animals injected with this dose of AduPARE1A survived. The
data thus indicate that the uPAR promoter provided reduced toxicity
to the replication-competent AduPARE1A virus.
Discussion
Oncolytic virotherapy is a promising approach for the systemic treat-
ment of cancers, such as pancreatic cancer, characterized by the rapid
dissemination of the tumor and the lack of any effective treatment.
However, the need of highly selective and efficient viruses is a requisite
for a safe and significant therapeutic benefit. Transcriptional targeting
strategies based on using TSP to redirect adenoviral gene expression
and replication have proved the importance of such approaches to
achieve tumor specificity. uPAR expression has been shown to be
transcriptionally upregulated in pancreatic ductal adenocarcinoma,
compared with normal pancreatic cells, suggesting that the factors driv-
ing uPAR transcription may be highly active in a tumoral context. In
this study, we have demonstrated that the uPAR promoter in an adeno-
virus vector delivers potent activity in all the pancreatic cancer cell lines
studied, although lower than that of the CMV promoter (10%-22%
of the latter). Interestingly, such differences were no longer found on
intratumoral or intravascular viral administration in mice bearing pan-
creatic SC xenografts. Thus, in vivo, the uPAR promoter activity in the
tumors was similar to that of the CMV promoter, suggesting that in the
tumor either CMV promoter activity is reduced or uPAR promoter
activity is favored. Most probably, both phenomena take place. In fact,
a comparative analysis of uPAR and CMV promoter activity in vivo
showed persistent luciferase expression in the AduPARLuc-injected tu-
mors, in contrast to a significant decrease in luciferase expression 1 week
after AdCMVGFPLuc injection. This effect could be related to the
susceptible epigenetic inactivation of robust but exogenous promoters
such as CMV, whereas such effects may be less relevant when using
endogenous promoters [25]. On the other hand, one could hypothesize
that tumor environment factors could positively regulate uPAR expres-
sion. In line with this, a lower oxygen pressure within the tumor envi-
ronment has been described to positively regulate uPAR expression in
several types of tumor [26]. Furthermore, uPAR has been found to be
upregulated in the tumor stroma [27] and in the invasive front of pan-
creatic tumors [28].
Significant uPAR tumoral activity would be in line with the re-
markable antitumor response achieved with the intratumoral admin-
istration of the conditionally replicating adenovirus AduPARE1A,
which completely eradicates 25% of the BxPC-3 SC–treated tumors
and offers a significant increase in survival rates. The significant re-
sponse achieved might also be accounted for additional mechanisms,
such as the fact that the AduPARE1A virus demonstrated a strong
in vitro cytocidal effect, similar to that of Adwt. Such similar in vitro
potency is highly relevant because a loss of potency has been reported
with some oncolytic adenoviruses that use TSP. The introduction of
a Kozak sequence in the E1A gene may have facilitated E1A trans-
lation. Indeed, it has been proposed that achieving near wild-type
levels of E1A could be required to maintain efficient adenoviral rep-
lication [29].
One of the major challenges was to demonstrate cancer selectivity
of the uPAR promoter for pancreatic cancer and metastasis. The first
evidence emerged from the in vitro data, which showed that uPAR
activity was significantly higher in pancreatic cancer cells than in nor-
mal pancreatic or embryonic lung cells. Notably, the cancer-specific
index of the uPAR promoter was significantly higher than that of
CMV, as shown by the 2-log increase in the tumor-to-liver ratio. In this
respect, biodistribution studies of tumor-free mice confirmed that
uPAR promoter activity was very weak in normal tissue. This is not
surprising because uPAR expression in the normal tissue of adult mice
has been reported to be restricted to the placenta and epididymis [30].
More importantly, our results demonstrate that upon intravascular
delivery, uPAR promoter activity is significantly higher than that of
the CMV promoter in tumor metastases in the liver, resulting in a
significant increase in tumor selectivity. Accordingly, AduPARE1A
shows a potent antitumoral effect in metastasis bearing mice, resulting
in a significant reduction of tumor burden at day 7, eradication of
metastasis in 33% of mice, and a significant increase in survival rates.
The specificity of the uPAR promoter was further demonstrated by the
systemic toxicity studies of immunocompetent mice. It is worth men-
tioning that, at the highest therapeutic viral dose used (5 × 1010),
whereas a 50% mortality rate was recorded for Adwt, as previously
reported [9], all the animals receiving the AduPARE1A virus survived
the course of the study, indicating that AduPARE1A presents a wider
therapeutic window.
The uPAR promoter could also be potentially suited to targeting
other types of cancer, as shown by increased uPAR activity in breast
and lung cancer cell lines, compared with normal cells. Along such
lines, uPAR has been found to be overexpressed in several types of
cancer, such as breast [18], prostate [31], and colon cancer [32].
Moreover, the 0.4-kb uPAR promoter used in this study is positively
regulated by the Sp1 transcription factor [17], which has been shown
to activate the uPAR promoter in colon cancer [32], suggesting the
ubiquitous cancer-specific activity of the uPAR promoter.
Altogether, our results indicate that we have developed a potent IV-
administered therapeutic agent, capable of great activity and selectivity
for pancreatic tumor tissue, yet with low toxicity in normal tissue.
Thus, AduPARE1A is a promising therapeutic agent for the treatment
of pancreatic cancer and has the potential to be effective in other types
of cancer. Future studies on arming this therapeutic virus with candi-
date transgenes may lead to further enhancing its antitumoral activity.
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Supplemental Data
uPAR Messenger RNA Determination
RNA was extracted from semiconfluent cell cultures, from BxPC-3
xenografts, and from PANC-1 liver metastases using the RNeasy Mini
RNA Extraction Kit (Qiagen). One microgram of total RNA was
reverse-transcribed using Moloney Murine Leukemia Virus reverse tran-
scriptase (Ambion, Austin, TX) and 1/10 of this reaction was linearly
amplified for 23 cycles (cell lines) or 28 cycles (tumor samples) after
denaturation (30 seconds at 95°C), annealing (30 seconds at 60°C),
and extension (30 seconds at 72°C) in a thermal cycler (GeneAmp PCR
System 9700; Applied Biosystems, London, UK). The following primers
were used: forward 5′ CAGGACCTCTGCAGGACCAC 3′, reverse 5′
CCTTGCAGCTGTAACACTGG 3′. Total RNA was normalized
using QuantumRNA 18S Internal Standards at a 1:4 ratio (Ambion).
Biodistribution Studies
BALB/c nude male mice (Charles River France, Lyon, France) re-
ceived 2 × 1010 vp of AdCMVGFPLuc or AduPARLuc or saline solu-
tion through tail vein injection in a final volume of 200 μl. At days 3, 5,
11, 20, 31 and 50 after adenoviral transduction, luciferase activity was
visualized and quantified using an in vivo bioluminescent imaging
system (IVIS; Xenogen). At day 50, immediately after imaging, mice
were killed and organs were removed and frozen. When stated, frozen
tissues were mechanically homogenized, 100 mg was used for protein
extraction using the Cell Culture Lysis Reagent (Promega) for 15 min-
utes at 25°C, and 10 μl was assayed for luciferase activity.
Metastasis Model by Intrasplenic Injection of Tumor Cells
Metastatic pancreatic adenocarcinoma animal models were generated
following the protocol previously described [1]. Briefly, BALB/c nude
mice were anesthetized with isoflurane and placed in the right lateral
decubitus. Thereafter, a left subcostal 1-cm incision was made, and
4 × 106 PANC-1 or PANC-1-Luc cells in 50-μl saline solution were in-
jected into the spleen with a 29-G needle. To maintain hemostasis and
prevent leakage of tumor cells outside the splenic capsule, a cotton-
tipped applicator was applied to the puncture site. After surgery, mice
were monitored daily for health and survival.
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Figure W1. uPAR expression in pancreatic cancer cells, normal cells and tumors. We have analyzed, by semiquantitative RT-PCR anal-
ysis, the uPAR expression in five pancreatic cancer cell lines and in normal pancreatic ductal epithelium cell HPDE (A) and in two tumor
models (B). Two different transcripts were detected corresponding to the entire form (534-bp fragment) or to one variant lacking one of
the L6/uPAR/α-neurotoxin domains of the receptor (400-bp fragment).
Figure W2. AduPARLuc biodistribution studies. BALB/c nude mice were injected IV with either saline solution (n = 3) or 2 × 1010 vp of
AdCMVGFPLuc (n= 4) or 2 × 1010 vp of AduPARLuc (n= 5). Bioluminescent activity was measured in anesthetized animals at days 3, 5,
11, 20, 31, and 50 after viral injection. (A) Representative images of bioluminescent emission. (B) Quantification of bioluminescence
emission was performed by measuring the total amount of emitted light captured by the camera. Results are expressed as photons
per second. Values are represented as mean ± SEM. ***P < .001, **P < .01, *P < .05. (C) At day 50, animals were killed and organs
were collected. Luciferase activity from tissue extracts was determined and normalized to total protein. Luciferase activity from the
saline group was considered as the background and subtracted from the viral groups. Results are expressed as light units per milligram
of tissue (LU/mg). Values are represented as mean ± SEM. **P < .01.
Figure W3. Liver metastases model. Liver metastases were generated by intrasplenic injection of PANC-1-Luc cells into BALB/c nude
mice. Luciferase activity was monitored in live animals. At day 19 after tumor implantation, after bioluminescent acquisition, animals
were killed, and liver was collected and analyzed for luciferase expression and metastases formation. (A) Representative images of liver.
(a) Light image. Original magnification, ×0.8. (b) Bioluminescent image. (B) Histologic analysis of liver tissue by hematoxylin and eosin
staining. (a) §§Liver area, ##tumoral area. Original magnification, ×10. (b) Original magnification, ×20.
Figure W4. AduPARLuc toxicity studies. BALB/c mice were injected through the tail vein with either saline solution (n= 4) or 2 × 1010 vp
of AdCMVGFPLuc (n = 4) or 2 × 1010 vp of AduPARLuc (n = 4). Five days later, blood samples were collected. Next, animals were
killed, and the liver tissue was excised. Liver portions were either frozen for luciferase or viral DNA determination, or fixed and em-
bedded in paraffin. (A) Luciferase activity from the liver extracts. Results were normalized to the number of viral particles per milligram
of tissue determined by real-time PCR. Results are expressed as light units per milligram (RLU) relative to the number of viral particles
(RLU/vp). Values are shown as mean ± SEM. (B) Hematoxylin and eosin staining of liver tissue. Lymphocyte infiltrates (arrows) and
necrotic hepatocytes (arrowhead) were only detected in the AdCMVGFPLuc-injected mice. Scale bar, 0.5 mm. (C) AST determination.
AST values expressed as international units (IU) per liter. *P = .02.
